CLINICAL TRIALS PROFILE FOR JANUMET
✉ Email this page to a colleague
All Clinical Trials for janumet
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00532935 ↗ | MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2008-01-26 | A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes |
NCT00684528 ↗ | A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumetâ„¢ Compared to Metformin | Unknown status | Clalit Health Services | Phase 3 | 2008-06-01 | Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting. |
NCT00684528 ↗ | A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumetâ„¢ Compared to Metformin | Unknown status | Meir Medical Center | Phase 3 | 2008-06-01 | Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting. |
NCT00993187 ↗ | Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2010-05-04 | This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride. |
NCT01065766 ↗ | Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182) | Completed | Merck Sharp & Dohme Corp. | 2009-03-01 | This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs. | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for janumet
Condition Name
Clinical Trial Locations for janumet
Trials by Country
Clinical Trial Progress for janumet
Clinical Trial Phase
Clinical Trial Sponsors for janumet
Sponsor Name